MedTrace Logo

Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital

NCT03819413 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2020-11-06

No results posted yet for this study

Summary

Neuromyelitis Optica Spectrum Disorders (NMOSD) are a group of inflammatory demyelinating disorders of the central nervous system. Although NMOSD occurs much more commonly in nations with a predominately non-Caucasian population, NMOSD are underestimated in Egypt and frequently misdiagnosed as multiple sclerosis (MS). In this study, by investigating serum anti-aquaporin (AQP) 4 and anti-MOG antibody of patients suspected to have NMOSD attending the Neurology and Psychiatry department of Assiut University Hospital, investigators aim to determine the relative frequency, clinical and radiological characteristics of NMOSD in upper Egypt community and compare it with other populations of different races.

Conditions

Interventions

DIAGNOSTIC_TEST

serum aquaporin 4 antibody (AQP-4-Ab)

All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum aquaporin 4 antibody (AQP-4-Ab) and serum myelin oligodendrocyte glycoprotein antibody (anti-MOG)

DIAGNOSTIC_TEST

serum MOG antibody (anti-MOG)

All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum myelin oligodendrocyte glycoprotein antibody (anti-MOG) if they tested negative for serum aquaporin 4 antibody (AQP-4-Ab)

DIAGNOSTIC_TEST

MRI brain, spine and orbit

All patients suspected to have NMOSD according to the recent diagnostic criteria will have MRI brain, spine and orbit with Gadolinium

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Noha A Abo Elfotoh, prof · Assuit university hospital

Eligibility

Min Age
3 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2020-07-15
Completion
2020-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03819413 on ClinicalTrials.gov